2. Cell Cycle/DNA Damage Epigenetics
  3. Sirtuin
  4. Selisistat

Selisistat (EX-527) is a potent and selective SirT1 (Sir2 in Drosophila melanogaster) inhibitor with an IC50 of 123 nM for SirT1. Selisistat alleviates pathology in multiple animal and cell models of Huntington's disease.

For research use only. We do not sell to patients.

Selisistat Chemical Structure

Selisistat Chemical Structure

CAS No. : 49843-98-3

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 61 In-stock
Solution
10 mM * 1 mL in DMSO USD 61 In-stock
Solid
5 mg USD 55 In-stock
10 mg USD 66 In-stock
25 mg USD 121 In-stock
50 mg USD 190 In-stock
100 mg USD 300 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 191 publication(s) in Google Scholar

Other Forms of Selisistat:

Selisistat Related Antibodies

Top Publications Citing Use of Products

185 Publications Citing Use of MCE Selisistat

WB

    Selisistat purchased from MedChemExpress. Usage Cited in: J Funct Foods. 2023 Mar.

    Selisistat (EX527) treatment significantly increases the levels of C-caspase3 and Bax but decreases the levels of Bcl-2, in 4-OI (4-Octyl Itaconate)-treated chondrocytes.

    Selisistat purchased from MedChemExpress. Usage Cited in: Metab Brain Dis. 2019 Feb;34(1):203-212.  [Abstract]

    Western analysis of the protein expression of Sirt1, FoxO1 and LC3 protein in the PC12 with the treatment of MPP+, ECH and EX527.

    Selisistat purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Aug 3;9:854.  [Abstract]

    Western blotting and quantitative analysis of XBP-1 and ATF6 levels normalized to GAPDH in mice (n=6). Western blotting and quantitative analysis of P-Smad3 and ac-Smad3 levels normalized to T-Smad3 (n=6). I stands for ISO, G stands for GE, and E stands for Ex-527.

    Selisistat purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta. 2018 Mar 6;1863(6):595-603.  [Abstract]

    LC3 deacetylation levels after erythropoietin (EPO) treatment are detected in PA-treated cells that have been treated with or without the SIRT1 inhibitor EX-527.

    Selisistat purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2017 May 19;18(5). pii: E1063.  [Abstract]

    Inhibition of sirt1 and AMPK blocked Rb2-induced hepatic autophagy. HepG2 cells are pretreated with 50 µM Rb2 for 4 h in the presence or absence of the sirt1 inhibitor EX-528 (EX) and the specific AMPK inhibitor Compound C (CC), and then subjected to OA (1 mM for HepG2 and 2 mM for primary mouse hepatocytes) exposure for 12 h. For lipid content determination, intracellular TG are stained by Oil red O (ORO). ORO is then eluted with isopropanol and the optical absorbance of the eluate is measured

    Selisistat purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Apr 18;8(32):52783-52791.  [Abstract]

    Immunoblot analysis of p-AKT (Ser473) and LC3-II in cells treated with 50 nM of TCO for 24 h in the presence and absence of EX-527.

    View All Sirtuin Isoform Specific Products:

    View All Isoforms
    Sirtuin SIRT1 SIRT2 SIRT3 SIRT6 SIRT5 SIRT7

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Selisistat (EX-527) is a potent and selective SirT1 (Sir2 in Drosophila melanogaster) inhibitor with an IC50 of 123 nM for SirT1. Selisistat alleviates pathology in multiple animal and cell models of Huntington's disease[1][2].

    IC50 & Target

    IC50: 123 nM (SirT1)[2]
    In Vitro

    Selisistat (1-10 μM) inhibits the deacetylation activity of both human SirT1 and Drosophila Sir2 in transfected cells[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Selisistat Related Antibodies
    In Vivo

    Selisistat (5 and 20 mg/kg, PO, daily; transgenic R6/2 mice beginning at 4.5 weeksof age to death) is protective in the R6/2 mouse model of Huntington’s disease (HD)[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    248.71

    Formula

    C13H13ClN2O
    CAS No.
    Appearance

    Solid

    Color

    Off-white to light yellow

    SMILES

    O=C(C1C(NC2=C3C=C(Cl)C=C2)=C3CCC1)N
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (402.07 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.0207 mL 20.1037 mL 40.2075 mL
    5 mM 0.8041 mL 4.0207 mL 8.0415 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (10.05 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (10.05 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 10 mg/mL (40.21 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.87%

    COA (252 KB) HNMR (0 KB) LCMS (97 KB)

    Handling Instructions (2659 KB)
    References
    Cell Assay
    [2]

    The immortal mouse macrophage cell line RAW264.7 are used. Cells are seeded in 96-well dishes at a density of 3 × 103 cells/cm2 and treated with high glucose at the concentrations of 5.6, 11.1, 25 and 30 mM, alone or with SRT1720 (1 μM) or Selisistat(10 μM) for 24 h. The stock solution of SRT1720 or Selisistat is prepared by dissolving each of them (in powder form) respectively in DMSO yielding a concentration of 100 μM and then stored at -80°C. MTT solution (0.5 mg/mL) is then added to each well and cells are incubated for 4 h at 37°C in a 5% CO2 incubator. Subsequently, the supernatant is removed, the formation of farmazan is solubilized with DMSO and measured at 540 nm with a Bio-Rad Model 680 Plate Reader[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [3]

    Mice[3] Mice are injected with Resveratrol (RSV) 30mg/kg (4 mL/kg) or equivalent volume of DMSO (Vehicle) (4 mL/kg) intraperitoneally 18 hours pre-sepsis. This dose of RSV in mice is as per documented literature. In one group of mice, RSV pre-treated mice receive Selisistat (10 mg/kg intraperitoneally; 4mL/kg, Vehicle: DMSO) within 10 minutes of cecal ligation and puncture.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 4.0207 mL 20.1037 mL 40.2075 mL 100.5187 mL
    5 mM 0.8041 mL 4.0207 mL 8.0415 mL 20.1037 mL
    10 mM 0.4021 mL 2.0104 mL 4.0207 mL 10.0519 mL
    15 mM 0.2680 mL 1.3402 mL 2.6805 mL 6.7012 mL
    20 mM 0.2010 mL 1.0052 mL 2.0104 mL 5.0259 mL
    25 mM 0.1608 mL 0.8041 mL 1.6083 mL 4.0207 mL
    30 mM 0.1340 mL 0.6701 mL 1.3402 mL 3.3506 mL
    40 mM 0.1005 mL 0.5026 mL 1.0052 mL 2.5130 mL
    50 mM 0.0804 mL 0.4021 mL 0.8041 mL 2.0104 mL
    60 mM 0.0670 mL 0.3351 mL 0.6701 mL 1.6753 mL
    80 mM 0.0503 mL 0.2513 mL 0.5026 mL 1.2565 mL
    100 mM 0.0402 mL 0.2010 mL 0.4021 mL 1.0052 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Selisistat Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Selisistat49843-98-3EX-527EX527EX 527SirtuinpathologyHuntington'sdiseasemammalianDrosophiladeacetylationInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Selisistat
    Cat. No.:
    HY-15452
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.